Source: Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Teresa Bruni, Francesco Varone. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020

Member's Comments

No comment yet.

Related content which might interest you: The genetics of systemic sclerosis Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Exercise limitation in systemic sclerosis Source: Eur Respir J 2005; 26: Suppl. 49, 107s Year: 2005 Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001 Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Etiologic factors in patients with systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 98s Year: 2006 Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Pulmonary involvement and exercise limitation in patients with systemic sclerosis Source: Eur Respir J 2004; 24: Suppl. 48, 53s Year: 2004 Experimental modeling of lung involvement due to systemic sclerosis. Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study Source: ERJ Open Res, 4 (1) 00135-2017; 10.1183/23120541.00135-2017 Year: 2018 Pulmonary involvement in systemic sclerosis Source: Eur Respir Monogr 2019; 86: 90-105 Year: 2019 Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017 Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018 Year: 2019 Incidence of pulmonary arterial hypertension related to systemic sclerosis: a 3-year nationwide longitudinal study Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Induced sputum in systemic sclerosis: A new potential for biomarkers in SSc Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions Source: Eur Respir J, 49 (5) 1700522; 10.1183/13993003.00522-2017 Year: 2017